Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 294R
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Renal
Current Generation
(* indicates number of generations grown in Castrate host)
 7
Average PDX Generation Time (days +/- SEM) 188 ± 45
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 294R
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
294R PTEN -0.994 1.004 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R SUFU -0.994 1.004 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R BRCA2 -0.828 1.126 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R FANCD2 -0.827 1.127 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R RB1 -0.765 1.177 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R SMAD2 -0.762 1.179 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R BRAF 0.660 3.160 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R EZH2 0.660 3.160 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
294R KMT2C 0.660 3.160 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 294R
Sample Site Prostate
Sample source Radical prostatectomy
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score 9
Primary Gleason Score 5
Secondary Gleason Score 4
Tertiary Gleason Score None
ISUP Grade Group 5
Tumour Grade PT3bN0
D'Amico Risk Classification 7
Tumour Volume (in cc) 30.2
Treatment Prior to Specimen Collection None

Patient Information

Patient Number 294
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 5.6
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 294R
Patient Age (binned in 5 year age groups) 60-64
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
294R SUFU 248 0.95 Missense variant '7/12 0.0002356 23.1 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R BRCA2 336 0.95 Frameshift variant '11/28 0.0002723 . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R EP300 362 0.71 Missense variant '10/31 4.06E-06 23.6 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R LRP1B 471 0.65 Missense variant '44/91 . 29.3 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R FGF3 450 0.46 Missense variant '2/3 . 27.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R MYC 689 0.46 Missense variant '3/3 7.31E-05 24.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R JPH2 45 0.36 Missense variant '2/6 0.0006877 16.43 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R ATM 436 0.32 Missense variant,splice region variant '57/63 . 32 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R UGT1A5 437 0.3 Missense variant '5/5 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R UGT1A4 437 0.3 Missense variant '5/5 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R UGT1A9 437 0.3 Missense variant '5/5 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R UGT1A7 437 0.3 Missense variant '5/5 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
294R UGT1A10 437 0.3 Missense variant '5/5 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500